Changes in clinical trials of cancer drugs in mainland China over the decade 2009–18: a systematic review

Li, Ning; Huang, Huiyao; Wu, Dawei; Yang, Zhijian; Wang, Jun; Wang, Jiansheng; Wang, Shuhang; Fang, Hong; Yu, Yue; Bai, Ying; Zhao, Yan; Cao, Yongtong; Jiang, Min; Liu, Yanfei; Li, Kunyan; Xu, Binghe; Sun, Yan; He, Jie

doi:10.1016/s1470-2045(19)30491-7

Cited by 67 publications

(63 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Favorable policies from the government and quick enrollment based on the large patient population are two features in the field of clinical trials that boost the nationwide novel drug investigation. 28 The NMPA has approved four PD-1 inhibitors developed by local companies for cancer treatment, including troparia, sintilimab, camrelizumab, and tislelizumab in 2018 to 2019. We believe that this will bring more benefit to Chinese patients at least by decreasing the economic burden of cancer treatment.…”

Section: Specific Challenges and Unique Featuresmentioning

confidence: 99%

Lung Cancer in People’s Republic of China

Gao

Wang

et al. 2020

Journal of Thoracic Oncology

Self Cite

125

View full text Add to dashboard Cite

Section: Specific Challenges and Unique Featuresmentioning

confidence: 99%

Lung Cancer in People’s Republic of China

Gao

Wang

et al. 2020

Journal of Thoracic Oncology

Self Cite

125

View full text Add to dashboard Cite

“…In addition, the lengthy approval process of the National Medical Products Administration makes it difficult for new foreign drugs to be marketed in China in a quick manner. Therefore, to our knowledge, there are <30 investigational new drug studies currently ongoing in mainland China …”

Section: Introductionmentioning

confidence: 99%

“…At the same time, the Food and Drug Administration of China has accelerated the process for establishing and approving new drugs abroad and innovative drugs, and has established green channels for the approval of some urgently needed drugs. As of 2017, the number of investigational new drug studies in mainland China has increased 10‐fold compared with 10 years prior, especially in phase 1 clinical studies . In the field of GISTs, Chinese physicians have performed studies involving independent innovative drugs such as famitinib, anlotinib, and HQP1351 (ClinicalTrials.gov identifiers NCT02336724, NCT04106024, and NCT03594422) and have joined studies of international new drugs such as avapritinib (ClinicalTrials.gov identifier NCT03465722).…”

Section: Introductionmentioning

confidence: 99%

The current status of and prospects in research regarding gastrointestinal stromal tumors in China

Shen

2020

Cancer

View full text Add to dashboard Cite

China still lacks statistical data regarding the incidence of gastrointestinal stromal tumors (GISTs). Data from 3 regions have demonstrated that the incidence of GISTs in China is similar to that in the United States. Furthermore, no significant differences between both nations with regard to epidemiological characteristics and genotyping of GISTs have been reported. Chinese physicians are demonstrating an increased interest in studies regarding GISTs. Currently, to the authors' knowledge, China publishes the most research articles regarding GIST annually worldwide. Despite the paucity of relevant research regarding the clinical practices for GISTs, a series of studies performed by Chinese physicians in the fields of recurrence risk classification, laparoscopic surgery, and adjuvant therapy have contributed to the diagnosis and treatment of GISTs. The lack of innovative drugs, slow approval of new drugs, and insufficient research funds have limited further advancements in GIST‐related research in China. In recent years, increased investment in scientific research has allowed for these advancements to be made by creating conditions for Chinese physicians to conduct high‐level clinical research. Chinese researchers hope to further shorten the gap between China and the rest of the world in the field of GIST research within a relatively short period. The purpose of the current review article was to present the most updated information regarding the diagnosis and treatment of GISTs in Chinese medical practice and to suggest prospective research in this field.

show abstract

“…Moreover, 33% new deaths occurred in Asia (more than 118,000 patients). With the rapid development of Asian urology in recent years, especially the increasing quality and quantity of PCa clinical trials in East Asian population, more and more high-quality papers from Asia have been published in many high-impact journals [2]. Thus, the international academic community is paying more and more attention to urological diseases, especially prostatic diseases in Asia.…”

mentioning

confidence: 99%